FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2787959738> ?p ?o ?g. }

• W2787959738 endingPage "1489" @default.
• W2787959738 startingPage "1479" @default.
• W2787959738 abstract "Aim To compare alirocumab, a proprotein convertase subtilisin-kexin type 9 inhibitor, with usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia not optimally managed by maximally tolerated statins in the ODYSSEY DM-DYSLIPIDEMIA trial (NCT02642159). Materials and Methods The UC options (no additional lipid-lowering therapy; fenofibrate; ezetimibe; omega-3 fatty acid; nicotinic acid) were selected prior to stratified randomization to open-label alirocumab 75 mg every 2 weeks (with increase to 150 mg every 2 weeks at week 12 if week 8 non-HDL cholesterol concentration was ≥2.59 mmol/L [100 mg/dL]) or UC for 24 weeks. The primary efficacy endpoint was percentage change in non-HDL cholesterol from baseline to week 24. Results The randomized population comprised 413 individuals (intention-to-treat population, n = 409; safety population, n = 412). At week 24, the mean non-HDL cholesterol reductions were superior with alirocumab (−32.5% difference vs UC, 97.5% confidence interval −38.1 to −27.0; P < .0001). Overall, 63.6% of alirocumab-treated individuals were maintained on 75 mg every 2 weeks. Alirocumab also reduced LDL cholesterol (−43.0%), apolipoprotein B (−32.3%), total cholesterol (−24.6%) and LDL particle number (−37.8%) at week 24 vs UC (all P < .0001). Consistent with the overall trial comparison, alirocumab reduced non-HDL cholesterol to a greater degree within each UC stratum at week 24. The incidence of treatment-emergent adverse events was 68.4% (alirocumab) and 66.4% (UC). No clinically meaningful effect on glycated haemoglobin, or change in number of glucose-lowering agents, was seen. Conclusions In individuals with T2DM and mixed dyslipidaemia on maximally tolerated statin, alirocumab showed superiority to UC in non-HDL cholesterol reduction and was generally well tolerated." @default.
• W2787959738 created "2018-03-06" @default.
• W2787959738 creator A5005414020 @default.
• W2787959738 creator A5008640203 @default.
• W2787959738 creator A5009182471 @default.
• W2787959738 creator A5019711625 @default.
• W2787959738 creator A5045462483 @default.
• W2787959738 creator A5061677162 @default.
• W2787959738 creator A5080099404 @default.
• W2787959738 creator A5080414941 @default.
• W2787959738 creator A5080948815 @default.
• W2787959738 creator A5081905258 @default.
• W2787959738 creator A5083408711 @default.
• W2787959738 creator A5083976399 @default.
• W2787959738 date "2018-03-23" @default.
• W2787959738 modified "2023-10-14" @default.
• W2787959738 title "Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial" @default.
• W2787959738 cites W1519335354 @default.
• W2787959738 cites W1520609538 @default.
• W2787959738 cites W1981250518 @default.
• W2787959738 cites W1996592745 @default.
• W2787959738 cites W2001328643 @default.
• W2787959738 cites W2012406449 @default.
• W2787959738 cites W2032241244 @default.
• W2787959738 cites W2063025601 @default.
• W2787959738 cites W2104005551 @default.
• W2787959738 cites W2111099202 @default.
• W2787959738 cites W2164089346 @default.
• W2787959738 cites W2164324917 @default.
• W2787959738 cites W2171811563 @default.
• W2787959738 cites W2266600614 @default.
• W2787959738 cites W2410117169 @default.
• W2787959738 cites W2417076517 @default.
• W2787959738 cites W2486690983 @default.
• W2787959738 cites W2522643247 @default.
• W2787959738 cites W2529053508 @default.
• W2787959738 cites W2535371675 @default.
• W2787959738 cites W2557654447 @default.
• W2787959738 cites W2559592043 @default.
• W2787959738 cites W2560283770 @default.
• W2787959738 cites W2563852152 @default.
• W2787959738 cites W2588974371 @default.
• W2787959738 cites W2596179513 @default.
• W2787959738 cites W2596236174 @default.
• W2787959738 cites W2596887658 @default.
• W2787959738 cites W2618685600 @default.
• W2787959738 cites W2754562397 @default.
• W2787959738 cites W2762777606 @default.
• W2787959738 cites W2785958895 @default.
• W2787959738 cites W2916481903 @default.
• W2787959738 cites W3171237122 @default.
• W2787959738 cites W4254397911 @default.
• W2787959738 doi "https://doi.org/10.1111/dom.13257" @default.
• W2787959738 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5969299" @default.
• W2787959738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29436756" @default.
• W2787959738 hasPublicationYear "2018" @default.
• W2787959738 type Work @default.
• W2787959738 sameAs 2787959738 @default.
• W2787959738 citedByCount "72" @default.
• W2787959738 countsByYear W27879597382018 @default.
• W2787959738 countsByYear W27879597382019 @default.
• W2787959738 countsByYear W27879597382020 @default.
• W2787959738 countsByYear W27879597382021 @default.
• W2787959738 countsByYear W27879597382022 @default.
• W2787959738 countsByYear W27879597382023 @default.
• W2787959738 crossrefType "journal-article" @default.
• W2787959738 hasAuthorship W2787959738A5005414020 @default.
• W2787959738 hasAuthorship W2787959738A5008640203 @default.
• W2787959738 hasAuthorship W2787959738A5009182471 @default.
• W2787959738 hasAuthorship W2787959738A5019711625 @default.
• W2787959738 hasAuthorship W2787959738A5045462483 @default.
• W2787959738 hasAuthorship W2787959738A5061677162 @default.
• W2787959738 hasAuthorship W2787959738A5080099404 @default.
• W2787959738 hasAuthorship W2787959738A5080414941 @default.
• W2787959738 hasAuthorship W2787959738A5080948815 @default.
• W2787959738 hasAuthorship W2787959738A5081905258 @default.
• W2787959738 hasAuthorship W2787959738A5083408711 @default.
• W2787959738 hasAuthorship W2787959738A5083976399 @default.
• W2787959738 hasBestOaLocation W27879597381 @default.
• W2787959738 hasConcept C126322002 @default.
• W2787959738 hasConcept C134018914 @default.
• W2787959738 hasConcept C168563851 @default.
• W2787959738 hasConcept C203092338 @default.
• W2787959738 hasConcept C2776839432 @default.
• W2787959738 hasConcept C2777180221 @default.
• W2787959738 hasConcept C2778096610 @default.
• W2787959738 hasConcept C2778110834 @default.
• W2787959738 hasConcept C2778163477 @default.
• W2787959738 hasConcept C2778657065 @default.
• W2787959738 hasConcept C2780072125 @default.
• W2787959738 hasConcept C2780745583 @default.
• W2787959738 hasConcept C2780902209 @default.
• W2787959738 hasConcept C2780948078 @default.
• W2787959738 hasConcept C2908647359 @default.
• W2787959738 hasConcept C43554185 @default.
• W2787959738 hasConcept C555293320 @default.
• W2787959738 hasConcept C62746215 @default.
• W2787959738 hasConcept C71924100 @default.

• next